Mergers and Acquisitions - Additional Information (Detail) - USD ($)					1 Months Ended		12 Months Ended
		Dec. 08, 2017	Jan. 08, 2016	Nov. 11, 2015	Mar. 30, 2017	Dec. 20, 2016	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 9.75
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	[1]						6,109,205
Payments for Agreement Termination							$ 400,000
Equity Method Investments							$ 21,903,524	$ 24,256,065
Business Acquisition, Share Price	[2]						$ 10.00
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	[3]						$ 61,092,050
Preferred Stock [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	[4]						$ 19,118,000
APA ACO Inc [Member]
Equity Method Investment, Ownership Percentage							50.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 1,738,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			7 years
Acquired Finite-lived Intangible Asset, Residual Value			$ 1,406,131
Network Medical Management, Inc. [Member]
Payments for Agreement Termination							$ 400,000
Conversion of Stock, Shares Issued Per Each Share				0.6
Conversion of Stock, Shares Issued				513,205		273,710
Network Medical Management, Inc. [Member] | Noncontrolling Interest [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	[5]						$ 5,129,000
Network Medical Management, Inc. [Member] | APA ACO Inc [Member]
Equity Method Investment, Ownership Percentage							50.00%	50.00%
APCN-ACO Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				513,205		273,710
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value				$ 3,075,000
Conversion of Stock, Shares Issued Per Each Share				1
Business Acquisition, Share Price				$ 5.99		$ 7.60
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles						$ 1,497,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life						5 years
Acquired Finite-lived Intangible Asset, Residual Value						$ 1,025,660
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable						$ 2,080,000
Medical Equipment Healthcare Supplies Wheelchair Center [Member]
Equity Method Investment, Ownership Percentage				75.00%
Equity Method Investments			$ 25
Medical Equipment Healthcare Supplies Wheelchair Center [Member] | APA ACO Inc [Member]
Equity Method Investment, Ownership Percentage				100.00%
Allegiance Home Health, Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						109,484
Equity Method Investment, Ownership Percentage				25.00%
Pacific Medical Imaging Oncology Center, Inc [Member]
Economic Interest Percentage				5.00%
Alliance Apex, LLC [Member] | Convertible Notes Payable [Member]
Debt Instrument, Face Amount					$ 4,990,000
Debt Instrument, Maturity Date, Description					The Alliance Note was due and payable to Alliance Apex, LLC on (i) March 31, 2018, or (ii) the date on which the Change of Control Transaction (see Note 3 NMM transaction) is terminated, whichever occurs first (Maturity Date).
Debt Instrument, Convertible, Conversion Price					$ 10.00
Apollo Medical Holdings, Inc [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Number of Share		2,566,666
Business Acquisition, Percentage of Voting Interests Acquired		82.00%
Business Combination, Consideration Description							The consideration for the transaction was 18% of the total issued and outstanding shares of ApolloMed common stock, or 6,109,205 (immediately following the Merger).
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		6,109,205
Fair Value Assumptions, Expected Term							2 years
Fair Value Assumptions, Expected Volatility Rate							37.90%
Fair Value Assumptions, Risk Free Interest Rate							1.80%
Preferred Stock, Liquidation Preference, Value							$ 12,745,000
Apollo Medical Holdings, Inc [Member] | Convertible Promissory Note [Member]
Debt Conversion, Converted Instrument, Shares Issued					520,081
Debt Conversion, Converted Instrument, Amount					$ 4,990,000
Apollo Medical Holdings, Inc [Member] | Warrant One [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		850,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 11.00
Apollo Medical Holdings, Inc [Member] | Warrant Two [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		900,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10.00
Maverick Medical Group, Inc [Member]
Business Combination, Contingent Consideration, Asset							100
Common Class B [Member] | Apollo Medical Holdings, Inc [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value							$ 6,373,000

[1] Represents the number of shares of the combined company that pre-Merger ApolloMed stockholders would own at closing of the Merger.

[2] Represents the closing price of ApolloMed’s common stock on December 8, 2017.

[3] Equity consideration Immediately following the Effective Time, pre-Merger ApolloMed stockholders continued to hold an aggregate of 6,109,205 shares of ApolloMed common stock.

[4] Estimated fair value of ApolloMed’s preferred shares held by NMM NMM currently owns all the shares of ApolloMed Series A preferred stock and Series B preferred stock, which was acquired prior to the Merger. As part of the Merger, the ApolloMed Series A preferred stock and Series B preferred stock is remeasured at fair value and included as part of the consideration transferred to ApolloMed. The fair value of the Series A preferred stock and Series B preferred stock is reflective of the liquidation preferences, claims of priority and conversion option values thereof. In aggregate, the Series A preferred stock and Series B preferred stock were valued to be $19,118,000. The valuation methodology was based on an Option Pricing Method ("OPM") which utilized the observable publicly traded common stock price in valuing the Series A preferred stock and the Series B preferred stock within the context of the capital structure of the Company. OPM assumptions included an expected term of 2 years, volatility rate of 37.9%, and a risk-free rate of 1.8%. The fair value of the liquidation preference for the Series A preferred stock and the Series B preferred stock was determined to be $12,745,000 and the fair value of the conversion option was determined to be $6,373,000 or an aggregate total fair value of $19,118,000.

[5] Estimated fair value of NMM’s 50% share of APA ACO Inc. Prior to the Merger, APAACO was owned 50% by ApolloMed and 50% NMM. NMM’s noncontrolling interest in APAACO has been remeasured at fair value as of the closing date and is added to the consideration transferred to ApolloMed as a result of NMM relinquishing its equity investment in APAACO in order to obtain control of ApolloMed. The fair value of NMM’s noncontrolling interest in APAACO has been estimated to be $5,129,000 using the discounted cash flow method and NMM recorded a gain on investment for the same amount to reflect the fair value of this investment prior the Merger.